Schmerzhafte diabetische Polyneuropathie

D. Ziegler

doi:10.1055/s-0038-1628272

Nervenheilkunde, Table of Contents

Nervenheilkunde 2012; 31(03): 140-146
DOI: 10.1055/s-0038-1628272

Schmerz

Schattauer GmbH

Schmerzhafte diabetische Polyneuropathie

Painful diabetic polyneuropathy

Authors

D. Ziegler

¹Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-Universität, Leibniz-Zentrum für Diabetesforschung; Klinik für Stoffwechselkrankheiten, Universitätsklinikum Düsseldorf

Abstract

Zusammenfassung

Etwa jeder dritte Diabetiker ist von der distal-symmetrischen Polyneuropathie (DPN) betroffen, die unter Ausbildung von einerseits teils quälenden neuropathischen Schmerzen und andererseits schmerzlosen Fußulzera mit erheblicher Einschränkung der Lebensqualität einhergeht. Die Prävalenz der schmerzhaften DPN liegt bei 13 bis 26%. Die Diagnose der DPN sollte anhand standardisierter Scores für neuropathische Symptome und Defizite objektiviert und im Verlauf kontrolliert werden. Die Therapie der diabetischen Neuropathie umfasst vier Ansätze: kausale Therapie mit dem Ziel einer Nahe-Normoglykämie, pathogenetisch begründbare Therapie, symptomatische Therapie neuropathischer Schmerzen und Vermeidung von Risikofaktoren und Komplikationen. Schmerztherapeutisch stehen insbesondere Antidepressiva wie Duloxetin und Amitriptylin, Kalziumkanal-α2δ-Modulatoren wie Pregabalin und Opioide als Mittel der zweiten Wahl bzw. zur Kombinationstherapie zur Verfügung. Nicht pharmakologische Therapien sind mit zu berücksichtigen. Eine sorgfältige Nutzen-Risiko-Abwägung steht am Anfang einer adäquaten Therapie mit dem Ziel, die Lebensqualität der Betroffenen dauerhaft zu erhalten.

Summary

Approximately one in three people with diabetes is affected by diabetic distal symmetric sensorimotor polyneuropathy (DPN), which is responsible for impaired quality of life by presenting with excruciating neuropathic pain and with painless neuropathic ulcers. The prevalence of painful DPN is 13 to 26%. Diagnosis of DPN should be verified using standardized scores for neuropathic symptoms and deficits and and its course should be monitored. Treatment is based on four cornerstones: intensive diabetes therapy and multi-factorial risk intervention; treatment based on pathogenetic mechanisms; symptomatic treatment; and avoidance of risk factors and complications. Pain treatment includes administration of antidepressants such as duloxetine and amitriptyline, calcium channel α2δ modulators such as pregabalin and opioids as drugs of second choice or for combination therapy. Non-pharmacological treatments always require consideration. Each initiation of treatment requires a thorough estimate of the risk-to-benefit relationship aimed at long-term maintenance of the patients‘ quality of life.

Schlüsselwörter

Schmerzhafte diabetische Neuropathie - Pharmakotherapie - nicht pharmakologische Therapie

Keywords

Painful diabetic neuropathy - pharmaco-therapy - non-pharmacological treatment

Full Text

References

Literatur
1 Gries FA. et al. Textbook of diabetic neuropathy. Stuttgart: Thieme; 2003
2 Ziegler D, Reiners K, Luft D. Diabetische Neuropathie. In: Häring HU. et al. (Eds.). Diabetologie in Klinik und Praxis. 6. Auf. Stuttgart: Thieme; 2011
3 Ziegler D. Diabetic peripheral neuropathy. In: Holt RI. et al. (eds.). Textbook of diabetes. 4th edition. Oxford: Wiley-Blackwell; 2010
4 Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28: 1480-1.
5 Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med 2006; 23: 1021-4.
6 Young LH. et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301: 1547-55.
7 Reiners K, Haslbeck M. Sensomotorische diabetische Neuropathien. Epidemiologie, Klinik und. Diagnostik. Diabetologe 2006; 2: 92-103.
8 Reiners K. Klinik, Diagnostik und Differenzialdiag-nose der Polyneuropathien. Klinikarzt 2007; 36: 263-9.
9 Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-8.
10 Lopes LA. et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005; 28: 2633-6.
11 Caravati CM. Insulin neuritis: a case report. Va Med Mon 1933; 59: 745-6.
12 Dabby R. et al. Acute painful neuropathy induced by rapid correction of serum glucose levels in diabetic patients. Biomed Pharmacother 2009; 63 (10) 707-9.
13 Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67: 534-41.
14 Martina IS. et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1998; 65: 743-7.
15 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter; 1. Auflage: www.diabetes.versorgungsleitlinien.de.
16 Papanas N. et al. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2005; 113: 195-8.
17 Young MJ. et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-4.
18 Feldman EL. et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-9.
19 Baron R. et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 2009; 146 1–2 34-40.
20 Ziegler D. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabetic Med 2004; 21: 114-21.
21 Ziegler D. et al. Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 Trial. Diabetes Care 2006; 29: 2365-70.
22 Kaur H. et al. A comparative trial to evaluate amitriptyline and duloxetine in painful diabetic neuropathy: A randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011 Feb 25, Epub ahead of print.
23 Quilici S. et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009; 9: 6.
24 Watson CP, Gilron I, Sawynok J. A qualitative systematic review of head-to-head randomized controlled trials of oral analgesics in neuropathic pain. Pain Res Manag 2010; 15: 147-57.
25 Baron R. et al. Therapie neuropathischer Schmerzen. In: Diener HC, Putzki N. (Eds.). Leitlinien für Diagnostik und Therapie in der Neurologie. 4. Auflage. Stuttgart: Thieme; 2008
26 Dworkin RH. et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (Suppl. 03) S3-14.
27 Attal N. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113-88.
28 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.
29 Kajdasz DK. et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post-hoc analysis of three randomized, placebo-controlled studies. Clin Ther 2007; 29: 2536-2546.
30 Ziegler D. et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007; 30: 664-9.
31 Tan T. et al. Phrmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010 Mar 24; 340; doi:10.1136/bmj.c1079.
32 Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-54.
33 Ziegler D. et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33: 839-41.
34 Baron R. et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009; 25: 1663-76.
35 Baron R. et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009; 25: 1677-87.
36 Sorgatz H. et al. Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen (LONTS). 2009 www.uni-duesseldorf.de/AWMF/ll 041-003.htm.
37 Schwartz S. et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27: 151-62.
38 Gilron I. et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 31 (352) 1324-1334.
39 Gilron I. et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374 9697 1252-61.
40 Jin DM. et al. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2010; 89: 10-5.
41 Reichstein L. et al. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005; 48: 824-8.
42 Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev 2008; 16 (Suppl. 03) CD006152.